Navigation Links
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Date:2/12/2009

NOVATO, Calif., Feb. 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that in the first interim efficacy analysis (IEA) for the Riquent(R) Phase 3 ASPEN trial, the Independent Data Monitoring Board (DMB) determined that the continuation of the trial is futile. BioMarin and partner La Jolla Pharmaceutical have decided to stop the study, unblind the data and evaluate all of the clinical results including secondary endpoints such as SLE (Systemic Lupus Erythematosus) disease activity indices and proteinuria.

"While the results of this first interim efficacy analysis are obviously disappointing, we decided to take a calculated risk on this program and with the carefully staged agreement, we have spent a total of $15 million, a relatively modest amount for a late Phase 3 asset addressing a large market opportunity," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We remain dedicated to advancing our development pipeline by making investments in future growth and continue to look for attractive late-stage in-licensing or acquisition opportunities."

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which was developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a divis
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... August 01, 2014 Once a decision ... cost? This webinar will discuss how to define your ... Join speakers Bob Allen, Senior Director of Facilities Integration ... Engineering at Fluor Industrial Services, and special guest Carrier ... Planning at Amgen, as they provide an examination of ...
(Date:8/1/2014)... -- Cambrex Corporation (NYSE: CBM ) reports results ... Highlights , Second quarter sales increased 59% ... last year. , Second quarter EBITDA increased 86% to ... last year (see table at the end of this release). ... impact of foreign currency, to between 13% and 16% over ...
(Date:8/1/2014)... ON (PRWEB) August 01, 2014 ... has led to a better understanding embryonic development. ... and reorganize into structurally and functionally distinct tissues ... physical defects. Prof. Todd McDevitt, Melissa Kinney, ... biophysical signals interact with biochemical cues to control ...
(Date:7/31/2014)... August 01, 2014 “2014 ... Polyurethane Resin Industry” is a professional and ... The report introduces Polyurethane Resin basic information, ... chain structure and industry overview. This research ... domestic market as well as global industry ...
Breaking Biology Technology:Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Study Links Biomechanics and Gene Expression in Stem Cells 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4
... (Nasdaq: RDEA ) today announced the formation ... SAB will provide independent,scientific advice and counsel to ... and development of drugs to treat chronic,inflammatory diseases, ... have brought together a group of international authorities ...
... Pharmaceuticals,Inc. (NYSE: BRL ) today confirmed that ... of the patents listed by GlaxoSmithKline in,connection with ... believes that it is the first to file ... IV certification for Avodart., Barr filed its ...
... /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), a biotechnology ... therapeutics, today announced that five abstracts have been,selected ... Research,(AACR) Annual Meeting held from April 12-16, 2008 ... that will disclose new findings,about its CD44, TROP-2, ...
Cached Biology Technology:Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program 2Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program 3Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg 2Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg 3ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting 2ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting 3
(Date:8/1/2014)... including two Simon Fraser University research associates, cite ... must collaborate closely on minimizing damage to the ... and Maureen Ryan, David H. Smith Conservation Research ... eight international co-authors of the newly published research ... . , Shale gas development is the extraction ...
(Date:7/31/2014)... of bigeye tuna movements in the northwestern Atlantic Ocean ... Research Center at the University of Massachusetts Amherst, found ... geographical range with pronounced north-south movements from Georges Bank ... area off Cape Hatteras southwest of Bermuda for foraging. ... to study one of the most important commercial tuna ...
(Date:7/31/2014)... the largest minority group in the United States, comprising ... are obese and are 1.2 times as likely to ... College of Nursing student researcher Lauren Gerchow, BSN, RN, ... contribute to this problem by compiling a systematic review ... Latina women recently published in Nursing Research . ...
Breaking Biology News(10 mins):Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3Study of bigeye tuna in Northwest Atlantic uses new tracking methods 2Study of bigeye tuna in Northwest Atlantic uses new tracking methods 3NYU research looks to combat US Latina immigrant obesity 2
... of Natural History have received a $1.6 million grant ... and to create a public database that provides information ... in two plant genomes. The three-year grant will allow ... for exploring the evolution, structure, and function of proteomes-- ...
... Mice given quercetin, a naturally occurring substance found ... the flu, according to a study published by The ... exercise increased the susceptibility of mice to the flu, ... a close chemical relative of resveratrol, is present in ...
... and Workgroup Scanners Recognized by ... the Leading Guide for Office ... Fujitsu Computer Products of,America, Inc., a market leader in ... scanners earned the "Editor,s Choice",designation in the Better Buys ...
Cached Biology News:NYU, American Museum of Natural History receive $1.6 million NSF grant 2Substance found in fruits and vegetables reduces likelihood of the flu 2Substance found in fruits and vegetables reduces likelihood of the flu 3Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide 2Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide 3
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
Agarose, Biotechnology grade, 500g...
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
... c-Jun proto-oncogene was first identified as the cellular ... Jun B and Jun D have been shown ... C-terminal regions, which are involved in dimerization and ... involved in transcriptional activation, diverge. ...
Biology Products: